Literature DB >> 16178018

A CTLA4high genotype is associated with myasthenia gravis in thymoma patients.

Wen-Yu Chuang1, Philipp Ströbel, Ralf Gold, Wilfred Nix, Berthold Schalke, Reinhard Kiefer, Andreas Opitz, Erdwine Klinker, Hans K Müller-Hermelink, Alexander Marx.   

Abstract

Myasthenia gravis (MG) in thymoma patients depends critically on intratumorous generation and export of mature autoreactive CD4+ T cells. Why non-MG thymomas fail to produce CD4+ T cells is unknown. We studied three single-nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4(CTLA4) gene in thymoma patients, nonthymoma early-onset MG patients, and control subjects. Surprisingly, the CTLA4high genotype +49A/A, which is protective against several autoimmune diseases, exerted a prominent predisposing effect to paraneoplastic MG in thymoma patients. The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4 levels possibly supporting the nontolerogenic selection of CD4+ T cells in MG-associated thymomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178018     DOI: 10.1002/ana.20577

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Authors:  Suchit H Patel; Andreas Rimner; Roger B Cohen
Journal:  Transl Lung Cancer Res       Date:  2017-04

2.  Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas.

Authors:  Irina Bonzheim; Eva Geissinger; Wen-Yu Chuang; Sabine Roth; Philipp Ströbel; Alexander Marx; Peter Reimer; Martin Wilhelm; Bernhard Puppe; Andreas Rosenwald; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  J Hematop       Date:  2008-04-24       Impact factor: 0.196

3.  Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk.

Authors:  H-Y Zhao; H-X Duan; Y Gu
Journal:  Clin Transl Oncol       Date:  2014-02-04       Impact factor: 3.405

4.  The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors.

Authors:  Andrew Gibson; Lee Faulkner; Maike Lichtenfels; Monday Ogese; Zaid Al-Attar; Ana Alfirevic; Philipp R Esser; Stefan F Martin; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

5.  Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis.

Authors:  Jian Zheng; Xiao Yu; Lan Jiang; Mang Xiao; Bing Bai; Jiachun Lu; Yifeng Zhou
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

6.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10

7.  Whole-genome analysis in Korean patients with autoimmune myasthenia gravis.

Authors:  Sang-Jun Na; Ji Hyun Lee; So Won Kim; Dae-Seong Kim; Eun Hee Shon; Hyung Jun Park; Ha Young Shin; Seung Min Kim; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

8.  Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms.

Authors:  Andrew Berry; Matt Tector; Martin K Oaks
Journal:  J Negat Results Biomed       Date:  2008-11-12

9.  cFLIP overexpression in T cells in thymoma-associated myasthenia gravis.

Authors:  Djeda Belharazem; Berthold Schalke; Ralf Gold; Wilfred Nix; Mario Vitacolonna; Peter Hohenberger; Eric Roessner; Torsten J Schulze; Güher Saruhan-Direskeneli; Vuslat Yilmaz; German Ott; Philipp Ströbel; Alexander Marx
Journal:  Ann Clin Transl Neurol       Date:  2015-07-22       Impact factor: 4.511

Review 10.  Recent advances in genetic predisposition of myasthenia gravis.

Authors:  Zoi Zagoriti; Manousos E Kambouris; George P Patrinos; Socrates J Tzartos; Konstantinos Poulas
Journal:  Biomed Res Int       Date:  2013-11-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.